These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 18269636

  • 21. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
    Singh KP, Periyandavar I, Rajadhyaksha GC, Jayaram S, Mishra AB, Kinagi S, Sharma A, Baliga VP.
    J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 24. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.
    Mukherjee AK, Reddy VS, Shah S, Jhingan AK, Ramakrishnan P, Prusty V, Singh NS.
    J Indian Med Assoc; 2009 Jul; 107(7):464-70. PubMed ID: 20112854
    [Abstract] [Full Text] [Related]

  • 25. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 26. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
    Kacerovsky-Bielesz G, Dressler A, Freunscht R.
    Diabetes Res Clin Pract; 2006 Feb; 71(2):184-91. PubMed ID: 16112241
    [Abstract] [Full Text] [Related]

  • 27. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 28. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 29. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L, Mannucci E, Dicembrini I, Rotella CM.
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [Abstract] [Full Text] [Related]

  • 31. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.
    Kawamori R, Eliaschewitz FG, Takayama H, Hayashida CY.
    Diabetes Res Clin Pract; 2008 Jan; 79(1):97-102. PubMed ID: 17919763
    [Abstract] [Full Text] [Related]

  • 33. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 34. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A, Khader S, Kharawagh A, AbdelFattah W, Badawy T.
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [Abstract] [Full Text] [Related]

  • 36. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG.
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [Abstract] [Full Text] [Related]

  • 37. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW.
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [Abstract] [Full Text] [Related]

  • 38. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study.
    Jang HC, Guler S, Shestakova M, PRESENT Study Group.
    Int J Clin Pract; 2008 Jul; 62(7):1013-8. PubMed ID: 18479365
    [Abstract] [Full Text] [Related]

  • 39. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.
    Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP, DARTS/MEMO Collaboration.
    Diabet Med; 2005 Jun; 22(6):749-55. PubMed ID: 15910627
    [Abstract] [Full Text] [Related]

  • 40. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.